These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34506898)

  • 1. Four-year patient-level pooled mortality analysis of the ILLUMENATE US Pivotal and EU randomized controlled trials.
    Lyden SP; Brodmann M; Parikh SA; Krishnan P; Schroeder H; Werner M; Holden A; Ouriel K; Tarra T; Gray WA
    J Vasc Surg; 2022 Feb; 75(2):600-607. PubMed ID: 34506898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
    Gray WA; Jaff MR; Parikh SA; Ansel GM; Brodmann M; Krishnan P; Razavi MK; Vermassen F; Zeller T; White R; Ouriel K; Adelman MA; Lyden SP
    Circulation; 2019 Oct; 140(14):1145-1155. PubMed ID: 31567024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-Year Independent Patient-Level Mortality Analysis of the Pooled ILLUMENATE Pivotal and EU Randomized Controlled Trials.
    Lyden SP; Brodmann M; Schroeder H; Holden A; Ouriel K; Tarra TR; Gray WA
    J Soc Cardiovasc Angiogr Interv; 2023; 2(4):100634. PubMed ID: 39131660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.
    Lyden SP; Faries PL; Niazi KAK; Sachar R; Jain A; Brodmann M; Werner M; Sood A; Krishnan P
    J Endovasc Ther; 2022 Dec; 29(6):929-936. PubMed ID: 35000470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
    Schneider PA; Laird JR; Doros G; Gao Q; Ansel G; Brodmann M; Micari A; Shishehbor MH; Tepe G; Zeller T
    J Am Coll Cardiol; 2019 May; 73(20):2550-2563. PubMed ID: 30690141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stellarex Drug-Coated Balloon for the Treatment of Peripheral Artery Disease: Five-Year Results from the ILLUMENATE Pivotal Randomized Controlled Trial.
    Krishnan P; Faries P; Niazi K; Sachar R; Jain A; Brodmann M; Werner M; Holden A; Tarricone A; Tarra T; Lyden S
    Am J Cardiol; 2024 Sep; 227():83-90. PubMed ID: 39019203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
    Laird JR; Schneider PA; Tepe G; Brodmann M; Zeller T; Metzger C; Krishnan P; Scheinert D; Micari A; Cohen DJ; Wang H; Hasenbank MS; Jaff MR;
    J Am Coll Cardiol; 2015 Dec; 66(21):2329-2338. PubMed ID: 26476467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices.
    Secemsky EA; Kundi H; Weinberg I; Jaff MR; Krawisz A; Parikh SA; Beckman JA; Mustapha J; Rosenfield K; Yeh RW
    JAMA Cardiol; 2019 Apr; 4(4):332-340. PubMed ID: 30747949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene - a single center experience.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Kuhn LM; Nührenberg T; Neumann FJ; Zeller T
    Vasa; 2021 Feb; 50(2):132-138. PubMed ID: 33118425
    [No Abstract]   [Full Text] [Related]  

  • 15. A Patient-Level, Pooled Analysis of Mortality Rates With the Passeo-18 Lux Paclitaxel Drug-Coated Balloon in Peripheral Arterial Disease.
    Forrestal BJ; Zhang C; Case BC; Yerasi C; Craig PE; Torguson R; Bernardo NL; Waksman R
    Cardiovasc Revasc Med; 2021 Dec; 33():49-54. PubMed ID: 34090794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts.
    Shishehbor MH; Schneider PA; Zeller T; Razavi MK; Laird JR; Wang H; Tieché C; Parikh SA; Iida O; Jaff MR
    J Vasc Surg; 2019 Oct; 70(4):1177-1191.e9. PubMed ID: 31543165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial.
    Mustapha JA; Brodmann M; Geraghty PJ; Saab F; Settlage RA; Jaff MR;
    J Invasive Cardiol; 2019 Aug; 31(8):205-211. PubMed ID: 31368893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study.
    Schroë H; Holden AH; Goueffic Y; Jansen SJ; Peeters P; Keirse K; Ito W; Vermassen F; Micari A; Blessing E; Jaff MR; Zeller T
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):497-504. PubMed ID: 29086462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries.
    Sixt S; Carpio Cancino OG; Treszl A; Beschorner U; Macharzina R; Rastan A; Krankenberg H; Neumann FJ; Zeller T
    J Vasc Surg; 2013 Sep; 58(3):682-6. PubMed ID: 23755977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Gebauer E; Cheung F; Lechner P; Nührenberg T; Zeller T
    JACC Cardiovasc Interv; 2020 Sep; 13(17):2052-2061. PubMed ID: 32593696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.